Beckman Coulter Life Sciences Acquires Microbioreactor Manufacturer m2p-labs
Advertisement
Beckman Coulter Life Sciences signed a definitive agreement to acquire m2p-labs, a privately held, microbioreactor manufacturer based in Baesweiler, Germany. m2p-labs is best known for its transformative BioLector plate-based microbioreactors, which support automated solutions for screening and bioprocess development.
Symbolic image
pixabay.com/Unsplash
“Innovation defines our future,” said Greg Milosevich, President, Beckman Coulter Life Sciences. “m2p-labs core product line complements our existing cell health, liquid handling and laboratory automation business. Our collective team has the opportunity to enhance time-saving solutions for cell line development and process development workflows.”
“m2p-labs and Beckman Coulter Life Sciences share a common vision of accelerating answers, enabling the faster discovery and development of life-changing advances in medicine,” said, Matthias Eggers, Managing Director, m2p-labs. “We are excited to join, and expand, a powerful team to provide invaluable resources to biologics customers around the world.”
m2p-labs was supported in several financings rounds by FIDURA Private Equity Funds and High-Tech Gründerfonds. “It was a privilege for us to work with management on growing m2p-labs to a leading microbioreactor vendor with global reach,” said Klaus Ragotzky, Managing Director and Chairman of the Advisory Board, FIDURA.
m2p-labs associates and products will transition into Beckman Coulter Life Sciences’ Biotechnology Business Unit. The company’s existing Baesweiler, Germany site will remain operational.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Adapting the Power of Density Gradient Separations for Gene Therapy Analytics - DGE-AUC (Density Gradient Equilibrium AUC) highly simplified analytical method
Biomek NGeniuS | Automatic preparation machines | Beckman Coulter
Future-oriented expansion of the LUM management
LUM GmbH and Alpharmaca Inc. start working together - Strong demand from the pharmaceutical and semiconductor sectors leads to expansion of the Chinese sales network
Mechanism for potential Friedreich's ataxia drug uncovered - Discovery takes researchers one step closer to human clinical trials and could improve understanding of other diseases
Eurofins acquires LGC Forensics
Eurofins expands its presence in India
Eurofins expands in clinical diagnostics
Eurofins expands its specialty diagnosis branch - Acquiring Dutch NMDL-LCPL
Strategic peptide purification - Practical and theoretical aspects of method development using reversed phase chromatography
YMC-Triart Prep | Chromatography sorbents | YMC